Do You Regain Weight After Stopping a GLP-1? What the Trials Show

It is the question most people ask after the weight starts coming off: do I have to take this forever? The honest answer is that the trial evidence points one direction — when the drug stops, much of the weight tends to come back. That single fact changes how you should read a provider's offer, because the program you sign up for is not a 12-week sprint. It is a maintenance relationship, and maintenance is one of the six dimensions we grade.

The drugs work while you take them Start with what the pivotal trials established on the way down. Once-weekly semaglutide 2.4 mg produced a mean body-weight change of about −14.9% over 68 weeks in STEP-1[[cite:1]], and tirzepatide reached up to roughly −20.9% at 72 weeks in SURMOUNT-1[[cite:2]]. Those are large, real reductions. The important word in both sentences is "over" — the loss accrues across many months of continuous, supervised dosing. What happens when that dosing ends is a separate question with its own evidence.

What the withdrawal trials found Three trials tested the "what if you stop" scenario directly, and they tell a consistent story.

In the STEP-1 trial extension, participants who had lost roughly 17% of their body weight regained about two-thirds of it within a year of their last dose, leaving a net loss closer to 6%³. The trajectory was clear: take the drug away, and the body largely reverses course.

STEP-4 ran the cleaner controlled version. Everyone took semaglutide for 20 weeks, then about a third (2:1 randomization to continue vs switch to placebo) were switched to placebo. Over the next 48 weeks, those who continued lost a further ~8% of body weight, while those switched to placebo regained about 7%⁴. Same people, same starting point — the only variable was whether the drug continued.

SURMOUNT-4 showed the same pattern with tirzepatide. After a 36-week lead-in that produced roughly 21% average weight loss, participants who continued the drug kept losing, while those switched to placebo regained a substantial share of what they had lost⁵. And on the other side of the ledger, STEP-5 showed that staying on semaglutide maintained the loss out to two years⁶. The benefit persists as long as the treatment does.

Why the weight comes back This is not a willpower story, and framing it that way is where a lot of programs quietly fail their patients. After weight loss, the body mounts a coordinated biological defense: appetite-regulating hormones shift in a direction that increases hunger and these adaptations persist for at least a year after the weight is lost[[cite:7]]. GLP-1 medications work partly by counteracting that drive. Remove the drug and the underlying biology — which never actually left — reasserts itself. Obesity behaves like a chronic, relapsing condition, and the trial data on withdrawal is exactly what you would expect from one.

What "stopping" is really trading away The scale is not the only thing at stake. In the SELECT trial, semaglutide reduced major adverse cardiovascular events in people with obesity and established cardiovascular disease but without diabetes[[cite:8]]. That kind of benefit is a function of ongoing treatment, not a one-time reset. So the decision to stop is not just "will I regain weight" — it is also "what else am I giving up." That is a conversation for a clinician who knows your history, not a checkout page.

This makes maintenance a scoring dimension If the evidence says the medication is a long-term commitment for most people, then the right question about a provider is not "can they get me started?" It is "can they keep me going affordably and safely for years?" That reframes several of the dimensions in our [WeighScore methodology](/methodology):

Cost stops being the intro price and becomes the maintenance price — what you actually pay, month after month, at your steady dose. Our breakdown of what compounded GLP-1 costs per month walks through that conversion. Clinical oversight stops being a one-time intake form and becomes a durable relationship with a prescriber who can adjust the plan, discuss tapering, and monitor you over the long haul. A provider optimized for a flashy first month and silent thereafter scores badly on exactly the dimension the withdrawal data says matters most.

How to pressure-test a provider on maintenance Before you subscribe, get plain answers to three things. First, what does this cost per month at my maintenance dose, indefinitely — not during the introductory period? Second, what is the plan if I ever want to reduce or stop; is there a structured taper and follow-up, or does the relationship just end? Third, who is monitoring me over months and years, and how do I reach them? A provider that answers all three cleanly is built for the reality the trials describe. Our full [six-point checklist](/how-to-choose-a-glp1-provider) puts those questions in order, and if you are still choosing between molecules, [semaglutide vs. tirzepatide](/semaglutide-vs-tirzepatide) covers that decision.

The honest bottom line For most people, GLP-1 therapy is not a course you finish — it is a treatment you maintain, the same way you would manage blood pressure or cholesterol. The weight-regain evidence is not a reason to avoid these drugs; it is a reason to choose a provider that is set up for the long game. Grade every company on whether it can carry you past month three. To see how the providers we track stack up on maintenance-friendly pricing and oversight, browse the graded [provider reviews](/research) and head-to-head [comparisons](/compare). None of this replaces advice from a licensed clinician who knows your medical history.